(Q42605011)

3 November 2017

Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine (English)

1 reference

3 November 2017

1

Jonatan D Lindh

1 reference

3 November 2017

Anita Annas

2

1 reference

3 November 2017

Lennart Meurling

series ordinal

3

1 reference

3 November 2017

Marja-Liisa Dahl

series ordinal

4

1 reference

3 November 2017

Ayman AL-Shurbaji

series ordinal

5

1 reference

3 November 2017

language of work or name

1 reference

25 July 2003

1 reference

3 November 2017

6

1 reference

European Journal of Clinical Pharmacology

inferred from page(s)

published in

1 reference

3 November 2017

59

1 reference

3 November 2017

401-406

1 reference

3 November 2017

5-6

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-003-0627-x

3 November 2017

0 references

cites work

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

1 reference

12 December 2020

O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants

1 reference

12 December 2020

Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans

1 reference

12 December 2020

Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

1 reference

12 December 2020

Determination of ketoconazole in the plasma, liver, lung and adrenal of the rat by high-performance liquid chromatography

1 reference

12 December 2020

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

12 December 2020

Venlafaxine serum levels and CYP2D6 genotype

1 reference

12 December 2020

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.

1 reference

12 December 2020

Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs

1 reference

12 December 2020

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

1 reference

12 December 2020

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

12 December 2020

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

1 reference

12 December 2020

10.1007/S00228-003-0627-X

Identifiers

DOI

1 reference

3 November 2017

1 reference